New Zealand Opens Primary Care Prescribing

Starting February 1, 2026, New Zealand will allow general practitioners and nurse practitioners to prescribe stimulant medications like methylphenidate (Ritalin, Concerta) and dexamfetamine for adults eighteen and older who are building focus skills. Mental health nurse practitioners will also gain authority to prescribe for children and adolescents working on attention development.

The policy change aims to reduce wait times that have stretched to over a year in some public health systems, with private assessments costing upwards of $1,000. Currently, only psychiatrists and pediatricians can initiate these medications. Between 2006 and 2022, adult prescriptions increased tenfold, yet only 0.6% of adults receive medication support despite an estimated 2.6% experiencing attention-related challenges.

A global shortage of methylphenidate pushed the implementation date from July 2025 to February 2026, giving health agencies additional time to develop training for participating practitioners.